Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 2, Open Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine (CX 2009) in Advanced HR Positive/HER2 Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination with Pacmilimab (CX 072) in Advanced Triple Negative Breast Cancer (CTMX 2009 002)
NCT Number:
NCT04596150
Phase:
II
Protocol Type:
Treatment
Age Group:
Adult
Disease Sites:
Breast
Study Objectives:
A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
Study Documents
(MUSC NetID required for document access)